PT. Garuda Indonesia (Persero) (GIAA) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
2 Dec, 2025Executive summary
Reported a net loss of US$180.8 million for the nine months ended September 30, 2025, compared to a net loss of US$129.6 million in the same period last year.
Total comprehensive loss for the period was US$185.5 million, with negative equity of US$1.54 billion as of September 30, 2025.
Accumulated losses reached US$3.69 billion, and current liabilities exceeded current assets by US$563 million.
Financial highlights
Operating revenues for the nine months were US$2.39 billion, down 6.7% year-over-year.
Operating expenses decreased to US$2.29 billion from US$2.38 billion year-over-year.
Finance costs remained high at US$372.8 million.
Cash and cash equivalents at period end were US$243.1 million, up from US$219.2 million at the start of the year.
Total assets stood at US$6.75 billion, with total liabilities of US$8.29 billion.
Outlook and guidance
Management continues to implement strategic plans including network rationalization, fleet expansion, ancillary revenue optimization, and capital raising.
Additional funding secured via a US$405 million shareholder loan from Danantara, convertible to equity, to support maintenance and operations.
Ongoing efforts to strengthen capital structure and improve equity position through both cash and non-cash corporate actions.
Latest events from PT. Garuda Indonesia (Persero)
- Net loss of $143M, negative equity, and restructuring efforts highlight ongoing financial challenges.GIAA
Q2 20252 Dec 2025 - Revenue up 16% to USD 1.62B, but net loss widens; going concern risk persists.GIAA
Q2 202413 Jun 2025 - Revenue up 15% to USD2.56B, but net loss deepens and liquidity risks remain.GIAA
Q3 202413 Jun 2025 - Net loss narrows to USD 75.9M in Q1 2025, but negative equity and liquidity risks persist.GIAA
Q1 20256 Jun 2025 - Revenue growth and positive EBITDA offset by net loss, negative equity, and going concern risk.GIAA
Q4 20246 Jun 2025